Differential Effects of Pentoxifylline on the Production of Tumour Necrosis Factor-alpha (TNF-alpha) and Interleukin-6 (IL-6) by Monocytes and T Cells

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1992 May 1

PMID 1385797

Citations 37

Authors

L Schandene

P Vandenbussche

A Crusiaux

M L Alegre

D Abramowicz

E Dupont

J Content

M Goldman

Affiliations

Soon will be listed here.

Abstract

Pentoxifylline (PTX) is a methylxanthine compound known to inhibit the production of tumour necrosis factor-alpha (TNF-alpha) by monocytic cells. In this study, we found that PTX differentially regulates the production of TNF-alpha and interleukin-6 (IL-6). Indeed, PTX at high concentrations triggers the production of IL-6 but not of TNF-alpha by peripheral blood mononuclear cells (PBMC). Further experiments indicated that monocytes are responsible for this PTX-induced IL-6 production. When PBMC were stimulated with LPS, PTX was found to inhibit the secretion of TNF-alpha as well as the accumulation of TNF-alpha messenger RNA (mRNA). In contrast, no inhibitory effect was observed on the induction of IL-6. Similar results were obtained when PBMC were stimulated with OKT3 monoclonal antibody (mAb). In addition, the in vivo administration of PTX in transplant patients receiving the first dose of OKT3 allowed to decrease the systemic release of TNF-alpha but not of IL-6. Since monocytes represent a major source of TNF-alpha and IL-6 in these settings, additional experiments were performed in vitro on purified T cells stimulated with the CLB-T3/3, an anti-CD3 mAb which does not require the presence of accessory cells to activate T cells. In this system, PTX was found to inhibit the secretion of both TNF-alpha and IL-6 by T cells. We suggest that cAMP could be involved in these differential effects of PTX on production of TNF-alpha and of IL-6.

Citing Articles

Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.

Hu Y, Sun C, Chen Y, Liu Y, Fan J J Clin Transl Hepatol. 2024; 12(9):802-814.

PMID: 39280073 PMC: 11393841. DOI: 10.14218/JCTH.2024.00123.

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial.

Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z Nat Commun. 2023; 14(1):6409.

PMID: 37828034 PMC: 10570369. DOI: 10.1038/s41467-023-42162-0.

Modulation of the Acute Inflammatory Response Induced by the Lipopolysaccharide through the Interaction of Pentoxifylline and Florfenicol in a Rabbit Model.

Cazanga V, Palma C, Casanova T, Rojas D, Barrera K, Valenzuela C Antibiotics (Basel). 2023; 12(4).

PMID: 37107001 PMC: 10135147. DOI: 10.3390/antibiotics12040639.

Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019.

Ghasemnejad-Berenji M, Pashapour S, Sadeghpour S Med Princ Pract. 2020; 30(1):98-100.

PMID: 33049737 PMC: 7923888. DOI: 10.1159/000512234.

Differential Effects of Pentoxifylline on Learning and Memory Impairment Induced by Hypoxic-ischemic Brain Injury in Rats.

Halis H, Bitiktas S, Bastug O, Tan B, Kavraal S, Gunes T Clin Psychopharmacol Neurosci. 2019; 17(3):388-399.

PMID: 31352705 PMC: 6705102. DOI: 10.9758/cpn.2019.17.3.388.

References

Bessler H, Gilgal R, Djaldetti M, ZAHAVI I . Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol. 1986; 40(6):747-54. DOI: 10.1002/jlb.40.6.747. View

Zabel P, Wolter D, Schonharting M, Schade U . Oxpentifylline in endotoxaemia. Lancet. 1989; 2(8678-8679):1474-7. DOI: 10.1016/s0140-6736(89)92929-2. View

Beutler B, Cerami A . Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987; 316(7):379-85. DOI: 10.1056/NEJM198702123160705. View

Zhang Y, Lin J, Yip Y, Vilcek J . Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6. Proc Natl Acad Sci U S A. 1988; 85(18):6802-5. PMC: 282066. DOI: 10.1073/pnas.85.18.6802. View

Debets J, van der Linden C, Dieteren I, Leeuwenberg J, Buurman W . Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol. 1988; 141(4):1197-201. View

Haegeman G, Content J, Volckaert G, Derynck R, Tavernier J, Fiers W . Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem. 1986; 159(3):625-32. DOI: 10.1111/j.1432-1033.1986.tb09931.x. View

de Jong R, Brouwer M, Miedema F, van Lier R . Human CD8+ T lymphocytes can be divided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation. J Immunol. 1991; 146(7):2088-94. View

Alegre M, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, De Pauw L . Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation. 1991; 52(4):674-9. DOI: 10.1097/00007890-199110000-00018. View

Endres S, Fulle H, Sinha B, Stoll D, Dinarello C, Gerzer R . Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. Immunology. 1991; 72(1):56-60. PMC: 1384335. View

10.

Han J, Huez G, Beutler B . Interactive effects of the tumor necrosis factor promoter and 3'-untranslated regions. J Immunol. 1991; 146(6):1843-8. View

11.

Doherty G, Jensen J, Alexander H, Buresh C, Norton J . Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991; 110(2):192-8. View

12.

Waage A, Sorensen M, Stordal B . Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet. 1990; 335(8688):543. DOI: 10.1016/0140-6736(90)90779-5. View

13.

Grau G, Frei K, Piguet P, Fontana A, Heremans H, Billiau A . Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobulinemia. J Exp Med. 1990; 172(5):1505-8. PMC: 2188677. DOI: 10.1084/jem.172.5.1505. View

14.

Starnes Jr H, Pearce M, Tewari A, Yim J, Zou J, Abrams J . Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990; 145(12):4185-91. View

15.

Hirano T, Akira S, Taga T, Kishimoto T . Biological and clinical aspects of interleukin 6. Immunol Today. 1990; 11(12):443-9. DOI: 10.1016/0167-5699(90)90173-7. View

16.

Krutmann J, Kirnbauer R, Kock A, Schwarz T, Schopf E, May L . Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3-induced T cell activation. J Immunol. 1990; 145(5):1337-42. View

17.

Ray A, LaForge K, Sehgal P . On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol. 1990; 10(11):5736-46. PMC: 361346. DOI: 10.1128/mcb.10.11.5736-5746.1990. View

18.

Waage A, Slupphaug G, Shalaby R . Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990; 20(11):2439-43. DOI: 10.1002/eji.1830201112. View

19.

Han J, Thompson P, Beutler B . Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med. 1990; 172(1):391-4. PMC: 2188134. DOI: 10.1084/jem.172.1.391. View

20.

Zhang Y, Lin J, Vilcek J . Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem. 1988; 263(13):6177-82. View